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Abbreviation list 26 
TA-TMA Transplant Associated Thrombotic 
Microangiopathy 
AKI Acute Kidney Injury 
CKD Chronic Kidney Disease 
HCT Hematopoietic Cell transplant 
SCD Sickle Cell Disease 
HUS Hemolytic Uremic Syndrome 
TTP Thrombotic Thrombocytopenic purpura 
HTN Hypertension 
MAC Myeloablative conditioning 
GvHD Graft Versus Host  Disease 
PEF Pericardial effusion 
CRRT Continuous renal replacement therapy 
PRES Posterior Reversible Encephalopathy 
Syndrome 
Bu/Cy/rATG Busulfan, cyclophosphamide and rabbit anti-
thymocyte globulin  
RSV Respiratory Syncytial virus 
CECs Circulating endothelial cells 
ICAM-1 Intracellular adhesion molecule 1 
VCAM-1 Vascular cell adhesion molecule 1 
  
 
This article is protected by copyright. All rights reserved. 
3 
 
eDAMPs Erythrocyte damage associated molecular 
patterns 
 eGFR Estimated Glomerular filtration rate 
LDH Lactate dehydrogenase 
CAE units Complement Activity enzyme units 
CFH Complement factor H 
 27 
Abstract 28 
Incidence and severity of transplant-associated thrombotic microangiopathy (TA-29 
TMA) in patients with hemoglobinopathies receiving hematopoietic cell transplant is 30 
unknown.  We report the outcomes for two patients with TA-TMA who received eculizumab.  31 
A 2.5 year old male with sickle cell disease developed TA-TMA-associated pericardial 32 
tamponade, severe hypertension and acute kidney injury two months post-transplant.  A 33 
seven-year-old female with beta-thalassemia major developed TA-TMA-related AKI, severe 34 
hypertension and seizures at six months post-transplant.  Both patients progressed to chronic 35 
kidney disease (CKD).  In patients with hemoglobinopathies, preexisting endothelial 36 
dysfunction may place them at greater risk for TA-TMA and subsequent CKD.   37 
  38 
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Introduction 39 
Hematopoietic cell transplant (HCT) is a curative option for patients with 40 
hemoglobinopathies like thalassemia and sickle cell disease (SCD).  These patients have 41 
endothelial dysfunction as a result of ongoing hemolysis [1-4].  It is unknown whether this 42 
pre-existing pathology places these patients at higher risk of transplant associated thrombotic 43 
microangiopathy (TA-TMA), a condition associated with widespread vascular injury.  44 
Incidence and severity of TA-TMA in this population undergoing HCT is unknown.  45 
TA-TMA belongs to the family of thrombotic microangiopathies including hemolytic 46 
uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP).  Endothelial 47 
injury leads to thrombosis, fibrin deposition, platelet consumption, and microangiopathic 48 
hemolytic anemia [5].  Clinical manifestations depend on the predominant organ 49 
microcirculation affected. Patients may present with intractable hypertension (HTN), acute 50 
kidney injury (AKI),  pulmonary hypertension, polyserositis or multi-organ failure. TA-TMA 51 
is associated with considerable morbidity and mortality; as affected patients are 4.3 times 52 
more likely to develop chronic kidney disease (CKD) and have higher non-relapse mortality 53 
rate (43.6% vs 7.8%) than unaffected patients  [6].  We describe two children with 54 
hemoglobinopathies who developed severe clinical manifestations of TA-TMA post HCT, 55 
despite receiving eculizumab therapy  56 
 57 
 58 
 59 
 60 
 61 
 62 
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Case Reports 63 
Case 1  64 
  A 2.5 year old African male with severe SCD underwent single-unit, sibling cord 65 
blood transplant following myeloablative conditioning (MAC) with busulfan, 66 
cyclophosphamide and rabbit anti-thymocyte globulin (Bu/Cy/rATG).  Tacrolimus and 67 
mycophenolate mofetil were given for graft-versus-host disease (GvHD) prophylaxis.  Sixty-68 
eight days post-transplant he presented with acute respiratory distress secondary to 69 
pericardial effusion (PEF) with tamponade. He was normotensive with normal blood counts 70 
and therapeutic tacrolimus levels.  He underwent pericardiocentesis, which did not identify an 71 
infectious cause and therefore treatment with high-dose methylprednisone was started.   After 72 
1 week of therapy he developed recurrent PEF necessitating a pericardial drain, progressive 73 
pancytopenia, refractory hypertension (requiring eight anti-hypertensives) and AKI requiring 74 
continuous renal replacement therapy (CRRT). Laboratory testing was consistent with TA-75 
TMA (Table I).  Despite discontinuing tacrolimus, his symptoms worsened.  Therefore, one 76 
week later eculizumab therapy was initiated.  Dosing schedule was as follows: 1200 mg/week 77 
(week 1), 900 mg/week (weeks 2-3), 600 mg/week (weeks 4-8), 300 mg/week (weeks 9-17) 78 
and 300 mg/2 weeks (weeks 18-21).  Hematological abnormalities normalized and effusion 79 
resolved after 4 weeks of therapy.  CRRT was discontinued after 2 weeks and nephrotic range 80 
proteinuria resolved after 21 weeks.  However, he progressed to CKD with HTN (requiring 81 
two anti-HTN medications).  Currently, he is 30 months post-transplant and has an estimated 82 
GFR (eGFR) of 45 ml/min/1.73m
2
 (pre-transplant eGFR 128ml/min/1.73m
2
).   83 
 84 
 85 
Case 2  86 
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  A seven-year-old Asian female with β-thalassemia major on chronic transfusion 87 
therapy, underwent a 10/10 matched unrelated donor bone marrow transplant following MAC 88 
with fludarabine, Bu/Cy/rATG and GvHD prophylaxis with cyclosporine and methotrexate.  89 
Post-transplant course was complicated by grade II acute GvHD, posterior reversible 90 
encephalopathy syndrome (PRES) with intracranial bleed, gastrointestinal hemorrhage, PEF 91 
and AKI.  Six months post-transplant she developed worsening hematuria, proteinuria with 92 
intractable hypertension (requiring five anti-hypertensive medications).  She was started on 93 
hemodialysis. Investigations revealed TA-TMA (Table 1).  There was minimal response to 94 
discontinuation of cyclosporine, therapeutic plasma exchange and basiliximab.  A renal 95 
biopsy performed showed acute, severe thrombotic microangiopathy (Figure 1) with C4d 96 
deposits in glomerular capillary loops and arterioles (not shown).  A month later she 97 
presented with seizures and brain MRI revealed diffuse white matter abnormality consistent 98 
with severe TMA and therefore she was started on eculizumab therapy and received 900 99 
mg/week (weeks 1-4) followed by 900 mg/2 weeks (weeks 5- 21).  Hematological response 100 
was seen after 4 weeks of therapy.  She had persistent nephrotic range proteinuria with no 101 
evidence of renal recovery.  She progressed to CKD with  HTN (requiring four anti-102 
hypertensives) and remained dialysis dependent with an eGFR of  35ml/min/1.73m
2
(pre-103 
transplant eGFR 103ml/min/1.73m
2
).  She died 16 months post-transplant due to RSV-related 104 
respiratory failure and TA-TMA related acute on CKD.  105 
 106 
 107 
 108 
Discussion 109 
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The vascular endothelium is a dynamic surface, which upon exposure to various 110 
stimuli, undergoes changes in gene expression and participates in inflammatory reactions, 111 
immunity and thrombosis [7].  Earlier studies in hemoglobinopathies have demonstrated an 112 
increase in the number of circulating endothelial cells (CECs) that express surface markers of 113 
endothelial activation and injury like soluble intracellular adhesion molecule 1 (ICAM-1) and 114 
vascular cell adhesion molecule 1 (VCAM-1) [8,9].  115 
Studies  in hemoglobinopathies have shown that  products of red cell breakdown: 116 
plasma free hemoglobin, heme and arginase-1 disrupt endothelial function and drive 117 
oxidative inflammatory stress known as erythrocyte damage associated molecular patterns 118 
(eDAMPs) [3,4].  These eDAMPs are implicated in the pathogenesis of vascular related 119 
complications associated with hemoglobinopathies.  Interestingly, there are several reports of 120 
SCD patients (HbSS, HbSC and HbSβ0) in non-transplant setting presenting with TTP 121 
following SCD crisis [10-11].  These patients had normal ADAMTS13 levels and responded 122 
to therapeutic plasma exchange.  It is unknown if pre-existing vascular dysfunction 123 
influences onset and severity of TA-TMA in patients with hemoglobinopathies undergoing 124 
HCT.  125 
TA-TMA is a multisystem disease characterized by vascular injury, variable clinical 126 
presentation and predominant renal involvement [12].  Diagnosis is based on clinical criteria 127 
published by Blood and Marrow Clinical Trial Network [13].  These criteria may be absent in 128 
early stages of TA-TMA as noted in our  patients, leading to diagnostic confusion especially 129 
in the presence of co-existing morbidities such as GvHD and infections [14].  130 
HTN, elevated lactate dehydrogenase (LDH), and proteinuria are early markers for 131 
TA-TMA [14].  PEF is seen in 30% patients with TA-TMA and may be the only 132 
manifestation as seen in patient 1 [15].  During transplant conditioning regimens, 133 
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opportunistic infections, GvHD and immunosuppressive agents initiate and aggravate 134 
endothelial damage, the pathological hallmark of TA-TMA [12].  Increased levels of markers 135 
of endothelial damage like von Willebrand factor antigen, thrombomodulin, plasminogen 136 
activator inhibitor 1, ICAM-1, and CECs have been reported in TA-TMA [12,16].  137 
Recent studies have shown complement activation and dysregulation in the 138 
pathogenesis of TA-TMA [17,18].  Eculizumab a monoclonal antibody against the 139 
complement component C5, blocks formation of membrane attack complex and is an 140 
effective treatment for TA-TMA Normalization of intravascular hemolysis indices and 141 
proteinuria to non-nephrotic range as originally described by  Jodele et al was used to guide 142 
eculizumab therapy in both patients [19]. Additionally, in patient1, hemolytic complement 143 
activity: CH50 (a surrogate marker of complement activation) levels were monitored twice 144 
weekly during therapy.  Levels were kept    ≤  4  complement activity enzyme (CAE) units  145 
as this  has been shown to  correlate with therapeutic eculizumab levels of  > 99μg/ml [19].  146 
Therapy was tolerated and there were no infusion related side effects or severe bacterial 147 
infections in both patients.  We recommend the recent dosing schedule suggested by Jodele et 148 
al utilizing CH50 and sC5-9 b levels to monitor response and guide frequency and duration of 149 
eculizumab therapy [20].   150 
While both our patients had severe TA-TMA with a poor renal response, it is possible 151 
that eculizumab therapy prior to overt clinical manifestations may have prevented CKD.  As 152 
evidenced in our first patient, long term monitoring of  kidney functions with control of HTN 153 
is essential, given the potential for some renal recovery.   154 
Conclusion 155 
We conclude that patients with hemoglobinopathies may be pre-disposed to TA-156 
TMA, given pre-existing endothelial dysfunction and subsequent vascular injury sustained 157 
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during HCT.   Future clinical trials utilizing HCT for hemoglobinopathies should evaluate the 158 
utility of early markers of endothelial damage to diagnose TA-TMA.  This will help to 159 
determine the role of pre-emptive eculizumab therapy prior to the onset of overt clinical 160 
manifestations and prevention of CKD.  161 
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LEGEND List:  216 
Figure. 1. Renal Biopsy:  Glomeruli showing evidence of acute TMA in glomerular 217 
capillary loops with marked vascular congestion, mesangiolysis and erythrocyte fragments. 218 
 219 
 220 
 221 
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 222 
TABLE 1:  Laboratory Values at Diagnosis 223 
Test Patient 1 Patient 2 
LDH 2926 (350 - 850 U/L)  1121 (140 - 280 U/L) 
Hemoglobin 8 (11.5 - 13.5 gm/dl) 7.4 (11.9 - 15 gm/dl)  
Reticulocyte count 6 (0.4 - 1.8%)  4.6 (0.5 - 2%) 
Platelet counts  114,000 cells/mm
3
 42,000  cells/mm
3
 
Haptoglobin 30 (33 - 171 mg/dl)  <20 (30 - 200 mg/dl) 
Peripheral shistocytes Rare to absent  3+ 
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Urine protein 324 (< 100 mg/dl)  300 (<100 mg/dl) 
Urine protein 
creatinine ratio 
14.14 (0.19 mg of protein/mg of 
creatinine) 
20.7 (0.2 mg of protein/mg of 
creatinine) 
sC5-9b at diagnosis 139 (74 - 244 ng/ml)  Not tested 
ADAMTS13 level  70 (>66%)  65 (>66%) 
Factor B 21.1 (13.3 - 31.5 mg/dl) 25.8 (12.7-27.8 mg/dl) 
Factor I  3.7 (2.4 - 4.9 mg/dl) 4.95 ( 2.9 - 5.8 mg/dl) 
Factor H  65.6 (37- 68 mg/dl) 32.1 (16 - 41 mg/dl) 
Factor H antibody Negative Negative 
C3 178 (86 - 184 mg/dl) 112 (90 - 180 mg/dl) 
C4 56 (16 - 59 mg/dl) Not tested 
CH50 221 (101- 300 CAE U/ml) 201 (60 – 144 CAEU/ml)  
Renal biopsy No Yes,  TMA changes 
LDH, Lactate Dehydrogenase;  CAE units,  Complement Activity enzyme units; Normal 224 
values for age are in parenthesis. 225 
 226 
